|
Synonyms: ARV-471 | ARV471 | compound 341 [WO2018102725A1] | PF-07850327 | PF07850327 | Veppanu®
vepdegrestrant is an approved drug
Compound class:
Synthetic organic
Comment: Vepdegrestrant (ARV471) is a bifunctional compound that is estrogen receptor (ER) degrader (PROTAC) [1]. It uses a cereblon-based binder to direct ER protein degradation. ARV471 is orally bioavailable, and was proposed for potential to treat breast cancer. Vepdegrestrant was the first PROTAC to gain clinical approval (from the US FDA, May 2026).
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Crew AP, Qian Y, Dong H, Wang J, Hornberger KR, Crews CM. (2018)
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders. Patent number: WO2018102725A1. Assignee: Arvinas Inc.. Priority date: 01/12/2016. Publication date: 07/06/2018. |
|
2. Fung S. (2026)
Vepdegestrant: First Approval. Drugs, [Epub ahead of print]. [PMID:42663865] |
|
3. Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y et al.. (2024)
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol, 20 (32): 2447-2455. [PMID:39072356] |